Compounds > idn 5109
Page last updated: 2024-12-11

idn 5109

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IDN 5109: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918412
CHEMBL ID382300
SCHEMBL ID9932772
MeSH IDM0358206

Synonyms (27)

Synonym
idn-5109
bay-59-8862
ortataxel
sb-t-101131
bay-59
ind5109
13-(n-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate
13-(n-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate
bay 59-8862
idn 5109
sb-t 101131
CHEMBL382300
hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (3as,4r,7r,8as,9s,10ar,12as,12br,13s,13as)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-met
(3as,4r,5e,7r,8as,9s,10ar,12as,12br,13s,13as)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano-13ah-oxeto(2',3':5',6')benzo(1',2':4,5)cyclodeca(1,2-d)-1,3-dioxol-4
186348-23-2
8h61y4e29n ,
unii-8h61y4e29n
ortataxel [inn]
ortataxel [who-dd]
idn5109
SCHEMBL9932772
DB11669
[(1s,2s,4s,7r,9s,10s,12r,15r,16s)-4,12-diacetyloxy-9-hydroxy-15-[(2r,3s)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-10,14,20,20-tetramethyl-11,18-dioxo-6,17,19-trioxapentacyclo[11.6.1.01,16.03,10.04,7]icos-13-en-2-yl] benzoat
[(1s,2s,3r,4s,7r,9s,10s,12r,15r,16s)-4,12-diacetyloxy-9-hydroxy-15-[(2r,3s)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-10,14,20,20-tetramethyl-11,18-dioxo-6,17,19-trioxapentacyclo[11.6.1.01,16.03,10.04,7]icos-13-en-2-yl] benz
ro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methano-13ah-oxeto[2'',3''
hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (3as,4r,7r,8as,9s,10ar,12as,12br,13s,13as)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahyd
DTXSID10870170

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" could improve bioavailability compared with paclitaxel."( IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Bombardelli, E; Colombo, T; D'Incalci, M; Donati, MB; Giavazzi, R; Monardo, C; Morazzoni, P; Nicoletti, MI; Riva, A; Rossi, C; Stura, S; Zucchetti, M, 2000)		0.31
" Because P-glycoprotein may critically influence intestinal absorption and oral bioavailability of taxanes, the purpose of the study was to evaluate the bioavailability, the pharmacokinetic behavior, and the antitumor activity of the new taxane after oral administration."( Oral efficacy and bioavailability of a novel taxane.
Bombardelli, E; Colombo, T; D'Incalci, M; Monestiroli, S; Morazzoni, P; Polizzi, D; Pratesi, G; Riva, A; Tortoreto, M; Zucchetti, M; Zunino, F, 2000)		0.31
" In addition, the reduced recognition of several compounds by multi-drug-resistance related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity."( Preclinical evaluation of new taxoids.
Bissery, MC, 2001)		0.31
" By comparing the interactions of each analogue with beta-tubulin, the structure-activity relationships are summarized as follow: C-2 benzoyl and taxane ring systems are the essential groups for microtubule binding, the improvements of bioactivity and bioavailability are dependent on the substituents at positions C-1, C-4, C-7, C-9, C-10, and C-14, whereas the C-13 side chain mainly provides a specific binding."( Structure-activity relationship of taxol inferring from docking taxol analogues to microtubule binding site.
Ma, Y; Xiang, F; Yin, R; Yu, J; Yu, L, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID680313TP_TRANSPORTER: efflux of mitoxantrone (Mitoxantrone: 3uM) in the presence of Ortataxel at a concentration of 10uM in MCF7/R cells2004Cancer chemotherapy and pharmacology, May, Volume: 53, Issue:5
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
AID231227Potency differential in resistant to that of sensitive A2780CIS cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID103575In vitro cytotoxicity against MCF-7 cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID7505In vitro cytotoxicity against A2780ADR cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID1061915Cytotoxicity against human MCF7 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID257059Cytotoxic potency in MCF7 human mammary carcinoma cell line after 72 hr exposure by SRB test2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390.
AID1061916Cytotoxicity against human NCI-H460 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID103770In vitro cytotoxicity against MCF7-R cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID1061914Cytotoxicity against human A375 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID231226Potency differential in resistant to that of sensitive A2780ADR cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID1061917Cytotoxicity against human HeLa cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID1061911Cytotoxicity against human HL60 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID103776Potency differential in resistant to that of sensitive MCF7-R cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID257061Resistance index (IC50 of MCF7 resistant cell line/IC50 of MCF7 sensitive cell line)2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390.
AID1061913Cytotoxicity against human HT-29 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID1061907Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 10 uM after 90 mins by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID7506In vitro cytotoxicity against A2780CIS cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID1061908Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 90 mins by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID10176In vitro cytotoxicity against A2780 cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID231228Potency differential in resistant to that of sensitive A2780TAX cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID1061918Cytotoxicity against human A2780 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID7677In vitro cytotoxicity against A2780TAX cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
AID1061912Cytotoxicity against human DU145 cells at 1 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID1061909Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 90 mins by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
The synthesis of novel taxoids for oral administration.
AID257060Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (8.70)18.2507
2000's17 (73.91)29.6817
2010's3 (13.04)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.46 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.00%)5.53%
Reviews5 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (76.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma [NCT00044564]Phase 254 participants (Actual)Interventional2001-12-31Completed
Multicenter, Single Arm, Open-Label Phase II Trial On The Efficacy Of Ortataxel In Recurrent Glioblastoma [NCT01989884]Phase 245 participants (Actual)Interventional2013-11-30Completed
An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer [NCT00039169]Phase 20 participants Interventional2001-12-31Active, not recruiting
An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma [NCT00044551]Phase 229 participants (Actual)Interventional2002-02-28Completed
An Open Phase II Multi-Center Trial of BAY 59-8862 in Patients With Aggressive Refractory Non-Hodgkin's Lymphoma [NCT00039156]Phase 20 participants Interventional2002-01-31Active, not recruiting
An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer [NCT00044525]Phase 282 participants (Actual)Interventional2002-04-30Completed
An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC) [NCT00044538]Phase 2102 participants (Actual)Interventional2001-12-31Completed
An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC) [NCT00054314]Phase 20 participants Interventional2002-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxymandelic acid
4-hydroxymandelic acid: RN given refers to cpd without isomeric designation. 4-hydroxymandelic acid : A 2-hydroxy carboxylic acid that is mandelic acid bearing a phenolic hydroxy substituent at position 4.		2.01102-hydroxy carboxylic acid;
phenols		metabolite
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.0210dihydroxyanthraquinoneanalgesic;
antineoplastic agent
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		2.0210benzoic acids;
sulfonamide		uricosuric drug
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.110cyclic ketone;
erythromycin
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.0210aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		5.93190taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		3.520secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
tryptoquivaline
fumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.		2.0210aromatic ether;
indole alkaloid;
organic heteropentacyclic compound		breast cancer resistance protein inhibitor;
mycotoxin
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		2.110cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.0210homodetic cyclic peptide
rpr 109881a
RPR 109881A: a semisynthetic taxoid compound that has a similar mechanism of action to docetaxel		4.0220
bms184476
[no description available]		3.1110
taxane
taxane: produced by Taxomyces andreanae		210diterpene;
terpenoid fundamental parent
cabazitaxel
cabazitaxel: an antineoplastic agent; structure in first source. cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.		2.110tetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent
idn 5390
IDN 5390: structure in first source		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		03.6530
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.6530
Benign Neoplasms, Brain
[description not available]		04.7621
Astrocytoma, Grade IV
[description not available]		04.5111
Local Neoplasm Recurrence
[description not available]		04.5111
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		04.7621
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		16.5111
Angiogenesis, Pathologic
[description not available]		02.4220
Cancer of Prostate
[description not available]		02.0110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0110
Benign Neoplasms
[description not available]		03.3420
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.3420
Cancer of Ovary
[description not available]		03.6230
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		03.6230
Carcinoma, Epidermoid
[description not available]		02.0310
Cancer of Head
[description not available]		02.0310
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.0310
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.0310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4120
Experimental Neoplasms
[description not available]		03.3220
Cancer of Colon
[description not available]		0210
Colonic Neoplasms
Tumors or cancer of the COLON.		0210
Glial Cell Tumors
[description not available]		0210
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		0210
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		02.9210